Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making
- PMID: 21453529
- PMCID: PMC3079693
- DOI: 10.1186/1478-4505-9-15
Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making
Abstract
When a new health product becomes available, countries have a choice to adopt the product into their national health systems or to pursue an alternate strategy to address the public health problem. Here, we describe the role for product development partnerships (PDPs) in supporting this decision-making process. PDPs are focused on developing new products to respond to health problems prevalent in low and middle income settings. The impact of these products within public sector health systems can only be realized after a country policy process. PDPs may be the organizations most familiar with the evidence which assists decision making, and this generally translates into involvement in international policy development, but PDPs have limited reach into endemic countries. In a few individual countries, there may be more extensive involvement in tracking adoption activities and generating local evidence. This local PDP involvement begins with geographical prioritization based on disease burden, relationships established during clinical trials, PDP in-country resources, and other factors. Strategies adopted by PDPs to establish a presence in endemic countries vary from the opening of country offices to engagement of part-time consultants or with long-term or ad hoc committees. Once a PDP commits to support country decision making, the approaches vary, but include country consultations, regional meetings, formation of regional, product-specific committees, support of in-country advocates, development of decision-making frameworks, provision of technical assistance to aid therapeutic or diagnostic guideline revision, and conduct of stakeholder and Phase 4 studies. To reach large numbers of countries, the formation of partnerships, particularly with WHO, are essential. At this early stage, impact data are limited. But available evidence suggests PDPs can and do play an important catalytic role in their support of country decision making in a number of target countries.
Similar articles
-
Enabling product development partnerships to bring forward the next generation of health technologies.Health Aff Sch. 2023 Dec 23;2(1):qxad088. doi: 10.1093/haschl/qxad088. eCollection 2024 Jan. Health Aff Sch. 2023. PMID: 38770112 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia.Med J Aust. 2020 Dec;213 Suppl 11:S3-S32.e1. doi: 10.5694/mja2.50881. Med J Aust. 2020. PMID: 33314144
-
Value and effectiveness of National Immunization Technical Advisory Groups in low- and middle-income countries: a qualitative study of global and national perspectives.Health Policy Plan. 2019 May 1;34(4):271-281. doi: 10.1093/heapol/czz027. Health Policy Plan. 2019. PMID: 31074778 Free PMC article. Review.
-
Risk management frameworks for human health and environmental risks.J Toxicol Environ Health B Crit Rev. 2003 Nov-Dec;6(6):569-720. doi: 10.1080/10937400390208608. J Toxicol Environ Health B Crit Rev. 2003. PMID: 14698953 Review.
Cited by
-
Implementing new health interventions in developing countries: why do we lose a decade or more?BMC Public Health. 2012 Aug 21;12:683. doi: 10.1186/1471-2458-12-683. BMC Public Health. 2012. PMID: 22908877 Free PMC article.
-
A four-step process for building sustainable access to diagnosis and treatment of Chagas disease.Rev Panam Salud Publica. 2019 Sep 20;43:e74. doi: 10.26633/RPSP.2019.74. eCollection 2019. Rev Panam Salud Publica. 2019. PMID: 31582959 Free PMC article.
-
Common characteristics of open source software development and applicability for drug discovery: a systematic review.Health Res Policy Syst. 2011 Sep 28;9:36. doi: 10.1186/1478-4505-9-36. Health Res Policy Syst. 2011. PMID: 21955914 Free PMC article.
-
Linking research to global health equity: the contribution of product development partnerships to access to medicines and research capacity building.Am J Public Health. 2013 Nov;103(11):1968-78. doi: 10.2105/AJPH.2013.301341. Epub 2013 Sep 12. Am J Public Health. 2013. PMID: 24028246 Free PMC article.
References
-
- Frost LJ, Reich MR. Access: How do good health technologies get to poor people in poor countries? Cambridge, Massachusetts: Harvard Center for Population and Development Studies; 2008.
-
- Brooks AD, Wells WA, McLean TD, Khanna R, Coghlan R, Mertenskoetter T, Privor-Dumm LA, Krattiger A, Mahoney RT. Ensuring that developing countries have access to new healthcare products: the role of product development partnerships. Innov Strat Today. 2009;3:1–5.
-
- Stop TB Partnership and World Health Organization. New technologies for tuberculosis control: a framework for adoption, introduction and implementation. Geneva: World Health Organization; 2007.
-
- TB Alliance. Pathway to Patients: Charting the Dynamics of the Global TB Drug Market. New York: Global Alliance for TB Drug Development; 2007.
LinkOut - more resources
Full Text Sources